Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06427304
Recruiting Observational

Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure

NCT06427304 · tracked via the Priya Life Science France tracker
Sponsor
Gérond'if
Phase
Observational
Started
2024-07-01
Last updated
2026-04-20

Condition(s) studied

Cardiac Amyloidosis

Study summary

Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure with left ventricular hypertrophy (septum ≥ 12 mm) on echocardiography

Eligibility

Sex
ALL
Min age
80 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥ 80 years * Hospitalised for decompensation of heart failure in the last 12 months * Subjects with hypertrophy of the septum or left ventricle at cardiac echography (defined as ≥ 12 mm) * Subjects able to undergo a bone scintigraphy scan * Subjects willing to participate Exclusion Criteria: * Subjects refusing to participate * Subjects admitted to palliative care unit. * Subjects under guardianship * Subjects with a definite diagnosis of cardiac amyloidosis

Primary outcome measure(s)

  • Assessment of the number of patients with cardiac amyloidosis according bon scintigraphy — At inclusion

Trial sites (36)

FacilityCityRegionStatus
Geriatric Department, Broca Hospital Paris IIe-de-France Recruiting
CHU Nantes Nantes Loire-Atlantique Recruiting
CHU Poitiers Poitiers New Aquitaine Recruiting
CHU Rouen, Charles Nicole hospital Rouen Normandy Recruiting
CHU Montpellier Montpellier Occitanie Recruiting
CHU Toulouse Toulouse Occitanie Recruiting
CHU Amiens Picardie Amiens France Recruiting
CHU Angers Angers France Recruiting
CHU Bordeaux Bordeaux France Recruiting
Centre Hospitalier de Carcassonne Carcassonne France Recruiting
Centre Hospitalier Intercommunal de Castres-Mazamet Castres France Recruiting
CHU Trousseau-Tours Chambray-lès-Tours France Recruiting
CHU Dijon Dijon France Recruiting
CHU Grenoble Alpes Grenoble France Recruiting
CHU Lille Lille France Recruiting
CHU Limoges Limoges France Recruiting
CHU Lyon Lyon France Recruiting
CHU Marseille Marseille France Recruiting
Clinique du Millénaire-Montpellier Montpellier France Recruiting
CHRU Nancy Nancy France Recruiting
CHU Nice Nice France Recruiting
Hôpital Privé Gériatrique LES SOURCES-Nice Nice France Recruiting
CHU Orléans Orléans France Recruiting
CHU Rennes Rennes France Recruiting
CHRU Tours-Bretonneau Hospital Tours France Recruiting
Clinique Saint Joseph Trelaze Trélazé France Recruiting
Médipôle Hôpital Mutualiste Villeurbanne Villeurbanne France Recruiting
Ambroise Paré Hospital Boulogne-Billancourt Île-de-France Region Recruiting
Corentin Celton Hospital Issy-les-Moulineaux Île-de-France Region Not Yet Recruiting
Charles Foix Hospital Ivry-sur-Seine Île-de-France Region Recruiting
Emile Roux Hospital Limeil-Brévannes Île-de-France Region Recruiting
GH Sud Ile-de-France Melun Île-de-France Region Recruiting
Lariboisière Hospital Paris Île-de-France Region Recruiting
Saint Joseph Hospital Paris Île-de-France Region Recruiting
Europeen Georges Pompidou Hospital Paris Île-de-France Region Recruiting
Bretonneau Hospital Paris Île-de-France Region Recruiting

More Gérond'if trials in France

Determinant of the Risk of the Becoming Frail in the Non-dependent Elederly Recruiting
Evaluation of Medical and Social Care for Elderly Patients, Between Hospital and Home: TEMPORARY ACCOMMODATION Out of Hospitalization by Nursing Home and Long-Term Care Units in Ile-de-France Region Recruiting
VIRal Pulmonary Infections in Older AGE Starting soon
Relevance of Artificial Intelligence-Assisted Echocardiography for Left Ventricular Ejection Fraction Assessment in Geriatric Patients Recruiting

Other trials for the same condition

Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine Recruiting
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy Recruiting
Registre HEAR, Healthcare European Amyloidosis Registry Recruiting
Prevalence of Cardiac Thrombi in Cardiac Amyloidosis Recruiting
Amylo-Shiatsu-Acute-Chronic: Effects of Shiatsu on Symptoms and Quality of Life of Amyloidosis Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06427304 on ClinicalTrials.gov ↗ ← All trials in France